Biosimilars are an important component of the effective biological treatments available in the EU. Biosimilars can relieve the financial burden on the healthcare system and make important therapies available to a wider range of patients.

15 years ago, the world's first biosimilar, originated in Austria, was approved in Europe by the European Commission. Thanks to the pioneering role of the European Medicines Agency (EMA) in developing its own regulatory pathway, 67 biosimilars for 16 active ingredients are now approved and on the market in Europe. In Austria, 45 biosimilars for 15 active ingredients are currently available.